CryoSave has maintained without compromise the high-quality processing and storage services and has handed over its whole bus...
19 Septembre 2019 - 1:26PM
CryoSave has maintained without compromise the high-quality
processing and storage services and has handed over its whole
business.
CryoSave has maintained without
compromise the high-quality processing and storage services and has
handed over its whole business.
Switzerland – 19 September 2019
CryoSave has since its establishment in 2000,
ensured the best security for its clients and has a proven track
record of professionalism and expertise in the field of stem cells
banking, recognized by the medical community.
CryoSave is one of the largest and longest
operating stem cell banks in Europe, having stored more than
330.000 umbilical cord blood samples and tissues over the past 20
years.
All laboratory protocols have been established
in compliance with the international guidelines and granted with
authorization for autologous and allogeneic transplantations.
On the 22th of February 2019, CryoSave AG
(Switzerland) and PBKM (Poland) have concluded a Backup and Storage
Agreement concerning the storage of all CryoSave stem cells samples
by PBKM in its state of the art and fully secured laboratories in
Warsaw, Poland.
We quote PBKM website:Containers with the
biological material of most of CryoSave‘s customers have been
safely transported upon the order of CryoSave to the PBKM FamiCord
Group laboratory in Poland. CryoSave decided to entrust this
service to PBKM Famicord due to the fact that PBKM Famicord is
regarded as the most reliable bank among European banks, their
storage standards and many years of very good financial standing
(https://famicord.eu/contact-with-famicord).
Following, on the 7th of March 2019, CryoSave
advised in good faith the Swiss Authorities of its intention to
move the samples to Poland and the 2nd of July 2019 the OFSP and
Swissmedic have been informed that no more cord blood samples were
stored in Switzerland and that CryoSave laboratory in Geneva has
stopped its activities. Consequently, it was no need and
justification to maintain the federal authorization to import,
export, process and store umbilical cord blood stem cells.
In the meantime, more than 500’000 email
communications have been sent to our customers.The 1st of July
2019, we issued a multi-language Press Release on Reuters and on
our website to confirm the safety of all the samples stored in
Poland and therefore reassure our clients that the umbilical cord
blood stem cells are the patient’s property and remain safely
stored under CryoSave’s supervision.
Finally, on the 27th of August Esperite,
CryoSave and Myrisoph Capital have concluded a strategic Agreement
related to Cryo-Save’s stem cell cryopreservation business.
Myrisoph becomes the exclusive global licensee of the CryoSave
brand.
We quote Myrisoph:We are confident that our
management team will turn CryoSave into a global leader by
implementing our best practices. Our priority will be to ensure
that existing and future clients will be fully satisfied commented
Hassan Alhassani, the President of Myrisoph Capital Inc.
CryoSave has always strived to act in its
client’s best interests and best practices.
The whole stem cell activity has been transfered
to Myrisoph, a reputable and experienced company which in
collaboration with PBKM will ensure the best continuity for the
customers.
To contact us: ir@esperite.com or
visit the websites at www.esperite.com
- CryoSave has maintained without compromise the high-quality
processing and storage services and has handed over its whole
business.